© 2004 by Oxford University Press
© 2004 Oxford University Press
BRIEF COMMUNICATION |
Frequency of BRCA1 and BRCA2 Mutations in Unselected Ashkenazi Jewish Patients With Colorectal Cancer
Affiliation of authors: Clinical Genetics Service, Department of Medicine (TK, NDK, HH, PK, CP, HR, KN, NAE, KO), and Department of Epidemiology and Biostatistics (JMS), Memorial Sloan-Kettering Cancer Center, New York, NY.
Correspondence to: Kenneth Offit, MD, MPH, Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., Box 192, New York, NY 10021 (e-mail: offitk{at}mskcc.org)
Mutations in BRCA1 and BRCA2 that predispose to breast and ovarian cancer are detected in approximately 2.5% of the Ashkenazi Jewish population. To explore whether carriers of Ashkenazi founder mutations in BRCA1 or BRCA2 have an increased risk for colorectal cancer, we screened 586 unselected Ashkenazi Jewish case patients with colorectal cancer for the three common founder mutations in BRCA1 and BRCA2. We identified six carriers (1.02%) among these case patients. After adjusting for age at diagnosis and sex by use of logistic regression analysis, we compared the incidence of carriers in this group of 586 case patients with that of 5012 Ashkenazi Jewish control subjects without a known history of colorectal cancer. The presence of a founder BRCA mutation was not associated with the risk of colorectal cancer (relative risk = 0.50, 95% confidence interval = 0.22 to 1.14). We thus recommend that counseling for colorectal cancer screening and prevention in individuals with BRCA mutations be based on the personal and family history of colorectal cancer or associated syndromic malignancies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Kadouri, A. Hubert, Y. Rotenberg, T. Hamburger, M. Sagi, C. Nechushtan, D. Abeliovich, and T. Peretz Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations J. Med. Genet., July 1, 2007; 44(7): 467 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Grabsch, M. Dattani, L. Barker, N. Maughan, K. Maude, O. Hansen, H. E. Gabbert, P. Quirke, and W. Mueller Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1494 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Travis, C. S. Rabkin, L. M. Brown, J. M. Allan, B. P. Alter, C. B. Ambrosone, C. B. Begg, N. Caporaso, S. Chanock, A. DeMichele, et al. Cancer Survivorship--Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations J Natl Cancer Inst, January 4, 2006; 98(1): 15 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C J van Asperen, R M Brohet, E J Meijers-Heijboer, N Hoogerbrugge, S Verhoef, H F A Vasen, M G E M Ausems, F H Menko, E B Gomez Garcia, J G M Klijn, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary J. Med. Genet., September 1, 2005; 42(9): 711 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Friedenson Re: BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer J Natl Cancer Inst, August 4, 2004; 96(15): 1184 - 1185. [Full Text] [PDF]
|
|
|
|
|
|
B. L. Niell, G. Rennert, J. D. Bonner, and S. B. Gruber RESPONSE: Re: BRCA1 and BRCA2 Founder Mutations and the Risk of Colorectal Cancer J Natl Cancer Inst, August 4, 2004; 96(15): 1185 - 1186. [Full Text] [PDF]
|
|
|
|
|
|
T. Kirchhoff, N. D. Kauff, N. Mitra, K. Nafa, H. Huang, C. Palmer, T. Gulati, E. Wadsworth, S. Donat, M. E. Robson, et al. BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews Clin. Cancer Res., May 1, 2004; 10(9): 2918 - 2921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Garber and S. Syngal One Less Thing to Worry About: The Shrinking Spectrum of Tumors in BRCA Founder Mutation Carriers J Natl Cancer Inst, January 7, 2004; 96(1): 2 - 3. [Full Text] [PDF]
|
|